“…In the prostate cell lines examined, expression levels in LNCaP and PC3 cells (derived from prostate metastases; Kaighn et al, 1979;Horoszewicz et al, 1983) were approximately one-fifth those in PNT2C2, P4E6 and 22Rv1 cells (derived from normal prostate cells or primary prostate cancer cells; Berthon et al, 1995;Sramkoski et al, 1999;Maitland et al, 2001). Furthermore, in screens of clonogenic activity with a range of chemotherapeutic agents and UV irradiation, we have found that, in general, PNT2C2 and P4E6 cells show high sensitivity, 22Rv1 cells show intermediate sensitivity and PC3 and LNCaP cells show high resistance.…”